Company Profile
Anebulo Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- ANEB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.33 USD (-5.69%)
Close
Last updated: August 21, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for ANEB.
Company overview
Cannabis-Toxicity Antidote
Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC.
Selonabant
Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or reversed key THC effects in a controlled Phase 2 proof-of-concept study in healthy adults.
Pediatric Intravenous Strategy
Anebulo is prioritizing an intravenous formulation for pediatric cannabis poisoning rather than moving the adult oral product directly into Phase 3. The company has scaled the IV formulation and initiated a Phase 1 single-ascending-dose safety study.
Future catalysts
- Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Anebulo Pharmaceuticals (ANEB)?
Anebulo Pharmaceuticals (ANEB) most recently closed at 0.33 USD, a -5.69% move versus the previous session.
What does Anebulo Pharmaceuticals do?
Cannabis-Toxicity Antidote Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC. Selonabant Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or...
On which exchange is ANEB stock listed?
Anebulo Pharmaceuticals (ANEB) is associated with NASDAQ, United States, Biopharma.
What is ANEB-001?
Selonabant Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist.
Which conditions is Anebulo Pharmaceuticals targeting with ANEB-001?
Cannabis-Toxicity Antidote Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC. Selonabant Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or...
How does Anebulo Pharmaceuticals describe recent progress with ANEB-001?
Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.
What is proof-of-concept?
Oral selonabant blocked or reversed key THC effects in a controlled Phase 2 proof-of-concept study in healthy adults.
What should investors watch for with proof-of-concept?
Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.